Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110994 · ClinicalTrials.gov registry record · Phase 2
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00110994 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 101 participants.
The verdict
NCT00110994, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + Sorafenib or DTIC + Placebo.
Interventions
- DRUG Placebo
- DRUG Dacarbazine
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110994
The ClinicalTrials.gov registry entry for NCT00110994 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00110994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110994 about?
NCT00110994 is a clinical study titled "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma". This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unre...
What is the current status of trial NCT00110994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2005-04. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00110994?
The interventions under investigation include: Placebo (DRUG), Dacarbazine (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00110994?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.